Selected article for: "chloroquine remdesivir and drug interaction"
Author: Rezaee, Haleh; Pourkarim, Fariba; Pourtaghi‐Anvarian, Samira; Entezari‐Maleki, Taher; Asvadi‐Kermani, Touraj; Nouri‐Vaskeh, Masoud
Title: Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
  • Cord-id: 9tuht6eu
  • Document date: 2021_1_9
    • ID: 9tuht6eu
    Snippet: Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for
    Document: Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID‐19 in order to minimize the adverse reactions.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and liver renal: 1, 2, 3, 4
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • abdominal pain and lupus erythematosus: 1, 2, 3, 4
    • active metabolite and liver renal: 1, 2, 3
    • active metabolite and liver renal impairment: 1
    • active metabolite and lopinavir ritonavir: 1
    • liver renal and lopinavir ritonavir: 1, 2, 3, 4, 5
    • liver renal and lupus erythematosus: 1
    • lopinavir ritonavir and lupus erythematosus: 1, 2, 3, 4